Short answer
RxSight, Inc. (RXST) filed an 8-K current report with the SEC on July 6, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Alcon collaboration adds $60M upfront cash and potential $140M milestone payments tied to feasibility, FDA submission, and approval.
RxSight, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Alcon collaboration adds $60M upfront cash and potential $140M milestone payments tied to feasibility, FDA submission, and approval
- 30% royalties on net Collaboration Product sales, with minimum royalty obligations and customary adjustments
- RxSight retains U.S. regulatory approvals and will exclusively manufacture products, creating supply and service revenue opportunities
- Alcon leads commercialization after approval, targeting U.S. launch within one year and potentially adding global commercial reach
- Development restrictions could reduce royalties by 60% or more and require partial payment reimbursement if RxSight pursues competing SVIOLs
Item 7.01 · Regulation FD Disclosure
- Forward-looking disclosure tied to RxSight-Alcon collaboration, including potential milestones and royalties
- Payments remain contingent, with timing and realization uncertain
- Key execution risks include technology transfer, manufacturing, regulatory approval, and third-party collaboration
- Commercial success depends on RxSight and Alcon executing their respective strategic plans
Item EX-99.1 · Exhibit EX-99.1
- Non-exclusive Alcon collaboration expands RxSight’s light-adjustable technology into presbyopia-correcting lenses
- $60 million upfront payment provides near-term development funding
- Up to $140 million in additional milestone payments, contingent on development and regulatory progress
- RxSight retains development and manufacturing, with royalties on net sales
- Alcon leads global commercialization, offering RxSight broader market access but less commercial control
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other RxSight, Inc. 8-K filings
Get the next RXST 8-K as it lands
Follow RXST for push alerts, or ask the research agent what this filing means.